The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker analysis from a phase I/I1b study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC).
 
James Yu
No Relationships to Disclose
 
Youngchul Kim
No Relationships to Disclose
 
Rutika Mehta
Honoraria - ASCO; Bristol-Myers Squibb
Consulting or Advisory Role - Astellas Pharma; AVEO (I); BostonGene; Bristol-Myers Squibb; Bristol-Myers Squibb (I); EMD Serono (I); Guardant Health; Immunomedics (I); Lilly; NCCN/Pfizer (I); Seagen (I)
Speakers' Bureau - Daiichi Sankyo; Gilead Sciences (I); Natera
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ruoyu Miao
No Relationships to Disclose
 
Jonathan R. Strosberg
Consulting or Advisory Role - Tersera
Speakers' Bureau - Ipsen
Research Funding - ITM Solucin (Inst); Novartis (Inst)
 
Iman Imanirad
Employment - Allergy, Asthma & Immunology Associates (I)
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - MyCareGorithm; signatera
 
Dae Won Kim
Research Funding - Bold Therapeutics
 
Richard D. Kim
Consulting or Advisory Role - Bayer; Exelixis; Lilly; Pfizer; QED Therapeutics; Roche/Genentech; SERVIER; Taiho Oncology
Speakers' Bureau - Eisai; Exelixis; Incyte
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)